Loading...
•
Dec 31, 2024
Arcturus Therapeutics Q4 2024 Earnings Report
Arcturus Therapeutics reported a decline in revenue and an increased net loss for Q4 2024.
Key Takeaways
Arcturus Therapeutics reported Q4 2024 revenue of $22.8 million, down from $30.9 million in Q4 2023, mainly due to lower milestone achievements from the CSL agreement. The company posted a net loss of $30.0 million compared to $11.7 million in the prior year quarter, with EPS decreasing to -$1.11 from -$0.44. Operating expenses increased to $56.2 million, driven by higher research and development costs.
Revenue decreased by 26.3% year-over-year to $22.8 million.
Net loss widened to $30.0 million from $11.7 million in Q4 2023.
Operating expenses increased to $56.2 million, up from $49.1 million.
EPS fell to -$1.11 from -$0.44 in the prior year quarter.
Arcturus Therapeutics
Arcturus Therapeutics
Forward Guidance
Arcturus expects continued progress in its clinical programs, with interim data from its Phase 2 CF and OTC deficiency studies anticipated in Q2 2025. The company aims to expand its STARR® sa-mRNA vaccine platform while preparing for regulatory filings for KOSTAIVE in the U.S. and U.K.
Positive Outlook
- Interim data from Phase 2 CF and OTC deficiency programs expected in Q2 2025.
- European Commission approval for KOSTAIVE COVID-19 vaccine.
- Regulatory filings for KOSTAIVE in the U.S. and U.K. anticipated in 2025.
- New Phase 1 trial initiated for pandemic flu vaccine candidate ARCT-2304.
- Strong cash position supporting ongoing R&D and commercialization efforts.
Challenges Ahead
- Significant year-over-year revenue decline in Q4 2024.
- Net loss increased substantially from the prior year.
- Higher research and development costs affecting profitability.
- Uncertain milestone payments from CSL could impact future revenue.
- Regulatory and market risks associated with vaccine commercialization.